Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;1(9):1340-1.
doi: 10.1001/jamaoncol.2015.2274.

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

Jennifer A Lo  1 , David E Fisher  2 , Keith T Flaherty  3
Affiliations

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

Jennifer A Lo et al. JAMA Oncol. 2015 Dec.
No abstract available

PubMed Disclaimer

References

    1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi: 10.1056/NEJMoa1003466. - DOI - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi: 10.1056/NEJMoa1200690. - DOI - PMC - PubMed
    1. Hamid O, Robert C, Daud A, et al. Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med. 2013 doi: 10.1056/NEJMoa1305133. - DOI - PMC - PubMed
    1. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells. N Engl J Med. 1988;318(24):1557–1563. doi: 10.1056/NEJM198806163182401. - DOI - PubMed
    1. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma. J Clin Oncol. 2001;19(15):3477–3482. - PubMed

Publication types

MeSH terms